Investors
Oncopeptides strives to ensure that analysts, investors, shareholders and financial media are provided with correct information to enhance understanding of our operations.
Presentation of the Year-end Report 2022
Oncopeptides published its report for the fourth quarter and the 2022 year-end report on February 16, and hosted a webcast on the same day. The event was hosted by CEO Monica Shaw, together with CFO Holger Lembrér and CSO Jakob Lindberg. The presentations was held in English.
Released
Year-end report 2022
"Pepaxti represents true innovation and an improved clinical experience that benefit patients"
CEO Monica Shaw
See the Webcast
For further information, please contact:
Rolf Gulliksen
Global Head of Corporate Communications
Q1 report May 4, 2023
rolf.gulliksen@oncopeptides.com
+46 70 262 96 28
Press release -
Oncopeptides receives a research grant from Sweden´s Innovation Agency to explore the PDC platform in solid tumors
Read press release
Upcoming events
Media and Investor Relations contacts
Rolf Gulliksen
Global Head of Corporate Communications
Jakob Lindberg interviewed by Di.TV regarding the leadership change
On Wednesday January 4, Jakob Lindberg was interviewed by by the Swedish economy TV channel Di.TV regarding the announced leadership change in Oncopeptides. Jakob Lindberg comments on his resignation as CEO of Oncopeptides and the appointment as Chief Scientific Officer.
Monica Shaw appointed CEO
On January 4, 2023, Oncopeptides announced that the Board of Directors has appointed Dr Monica Shaw as Chief Executive Officer, CEO, of Oncopeptides. She replaces Jakob Lindberg, who has been the CEO since November 15, 2021. Lindberg assumes his previous position as Chief Scientific Officer. These changes are effective immediately.
Fire side chat at SEB Annual Healthcare Seminar 2022
At SEB's Annual Healthcare Seminar, November 23, 2022, Jakob Lindberg, CEO Oncopeptides, participated in a fire side chat with Dr. Christopher Uhde, Pharma/Biotec equity research at SEB.
CEO Jakob Lindberg interviewed by Di.TV regarding the Q3 report and the EU and US market
On November 9, 2022, CEO Jakob Lindberg was interviewed by Börsmorgon in the Swedish Dagens Industri Di.TV regarding the Q3 report and the EU and US market. See the interview by clicking the link below. The interview is in Swedish.
Tyska lanseringen av Pepaxti - presentation
Fredagen den 21 oktober kl.14.00, 2022, håller Oncopeptides en presskonferens för att prata om den tyska lanseringen av Pepaxti®.
Webcast - update from the ODAC meeting
September 23, 2022, the Oncologic Drugs Advisory Committee (ODAC), of the US Food and Drug Administration (FDA), has finalized the discussion on the benefit-risk profile of Pepaxto® (melphalan flufenamide, also called melflufen). A majority of the panel considered that OCEAN did not confirm a favorable benefit-risk profile in the current indicated patient population.
Investors, analysts and media were invited to listen to a webcast presentation and participate in a following Q&A session on September 26, at 14:00 (CET). The webcast was recorded.
Webcast - CHMP issues a positive opinion recommending full approval of Oncopeptides Pepaxti in EU
June 23, 2022, the European Medicines Agency´s (EMA) Committee for Medicinal Products for Human Use (CHMP), has unanimously adopted a positive opinion recommending a full marketing authorization approval (MAA) of Pepaxti® (melphalan flufenamide, also called melflufen) in EU.
Investors, financial analysts, and media were invited to participate in a webcast with a Q&A session on June 27, 2022, at 11:00 (CET). The event was hosted by CEO Jakob Lindberg, CMO Klaas Bakker and CFO Annika Muskantor.
Released
Annual Report 2021
Rolf Gulliksen
Global Head of Corporate Communications
rolf.gulliksen@oncopeptides.com
+46 70 262 96 28
Letter from the CEO - Science is leading the way
"When I look back at 2021, this has been the most revolutionary year in Oncopeptides’ history"
Jakob Lindberg, CEO
Webcast - Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US
January 21, 2022, Oncopeptides announced that the Company has contacted the US Food and Drug Administration and rescinded the October 22, 2021, letter requesting voluntary withdrawal of the NDA of Pepaxto® in the US.
Investors, financial analysts and media are invited to participate in a webcast with a Q&A session on January 24, 2022, at 09:00 (CET).
The event will be hosted by CEO, Jakob Lindberg and CMO, Klaas Bakker. The presentation will be held in English.
Jakob interviewed by Di.TV - as new CEO about going forward
In conjunction with the anouncement of Jakob Lindberg as new CEO of Oncopeptides, he was interviewed by the Swedish economy TV channel Di.TV about the company's priorities going forward.
Jakob Lindberg appointed CEO
On November 15, Oncopeptides announced that the Board of Directors has appointed Jakob Lindberg as Chief Executive Officer, CEO of Oncopeptides. Jakob Lindberg replaces Marty J Duvall, who has been the CEO since July 1, 2020. These changes are effective immediately.
Presentations, webcasts and transcripts
See our latest Investor presentations, webcast, transcripts and interviews